Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6704

1.

Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?

Abdel-Razek W, Waked I.

Aliment Pharmacol Ther. 2018 Aug;48(3):379-380. doi: 10.1111/apt.14831. No abstract available.

2.

Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.

Savoye G, Fumery M, Gower-Rousseau C.

Aliment Pharmacol Ther. 2018 Aug;48(3):384-385. doi: 10.1111/apt.14854. No abstract available.

3.

Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD).

Noureddin M, Loomba R.

Aliment Pharmacol Ther. 2018 Aug;48(3):378-379. doi: 10.1111/apt.14819. No abstract available.

4.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.

Julsgaard M, Kjeldsen J, Brock B, Baumgart DC.

Aliment Pharmacol Ther. 2018 Aug;48(3):386-388. doi: 10.1111/apt.14837. No abstract available.

5.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M.

Aliment Pharmacol Ther. 2018 Aug;48(3):388-389. doi: 10.1111/apt.14855. No abstract available.

6.

Editorial: ustekinumab and Crohn's disease-what can we learn from long-term extension studies?

Gearry RB, Daker C.

Aliment Pharmacol Ther. 2018 Aug;48(3):382-383. doi: 10.1111/apt.14844. No abstract available.

7.

Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery?

Myrelid P.

Aliment Pharmacol Ther. 2018 Aug;48(3):383-384. doi: 10.1111/apt.14833. No abstract available.

8.

Editorial: proton pump inhibitors (PPIs) and primary liver cancer.

Waldum HL.

Aliment Pharmacol Ther. 2018 Aug;48(3):380-381. doi: 10.1111/apt.14841. No abstract available.

9.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

10.

Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease.

Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS 4th, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB.

Aliment Pharmacol Ther. 2018 Jun;47(12):1639-1651. doi: 10.1111/apt.14674. Epub 2018 Apr 25.

11.

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM.

Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30. Review.

12.

Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease.

Vollebregt PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, Felt-Bersma RJF.

Aliment Pharmacol Ther. 2018 May;47(9):1253-1260. doi: 10.1111/apt.14599. Epub 2018 Mar 9.

13.

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.

Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group.

Aliment Pharmacol Ther. 2018 Apr;47(8):1170-1180. doi: 10.1111/apt.14560. Epub 2018 Mar 2.

14.

An expert consensus for the management of chronic hepatitis B in Asian Americans.

Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD.

Aliment Pharmacol Ther. 2018 Apr;47(8):1181-1200. doi: 10.1111/apt.14577. Epub 2018 Feb 26.

15.

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.

Webb GJ, Rahman SR, Levy C, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Apr;47(8):1213-1219. doi: 10.1111/apt.14579. Epub 2018 Feb 22.

16.

Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.

Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Seifert B, Wensaas KA, Winchester C, de Wit N; European Society for Primary Care Gastroenterology.

Aliment Pharmacol Ther. 2018 Apr;47(8):1054-1070. doi: 10.1111/apt.14539. Epub 2018 Feb 20. Review.

17.

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML; NASH CRN.

Aliment Pharmacol Ther. 2018 Mar;47(5):645-656. doi: 10.1111/apt.14492. Epub 2018 Jan 14.

18.

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ.

Aliment Pharmacol Ther. 2018 Jan;47(2):229-237. doi: 10.1111/apt.14421. Epub 2017 Nov 21.

19.

The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.

Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C.

Aliment Pharmacol Ther. 2018 Jan;47(1):67-77. doi: 10.1111/apt.14387. Epub 2017 Oct 20.

20.

The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.

Yiannakou Y, Tack J, Piessevaux H, Dubois D, Quigley EMM, Ke MY, Da Silva S, Joseph A, Kerstens R.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1103-1111. doi: 10.1111/apt.14349. Epub 2017 Oct 6.

Supplemental Content

Loading ...
Support Center